No surprises because they keep spruiking about "rapid growth phase" and revenue to "accelerate significantly" in FY18.
But one has to wonder what that means based on the current y.o.y deceleration in revenue.
Revenue from ordinary activities for FY16 were up 360% to $155k.
Revenue from ordinary activities for FY17 were up 53% to $238k.
I would have expected some of the OEM partnerships to be showing something by now particularly Labcon.
However, Sale of Product did increase by 144% from $57k to $140k but interestingly Licence Income only increased by 16% from $100k to $116k (refer to Note 6 in Prelim Report). It would appear that Labcon etc are getting a huge discounted rate for the licence fees.
Looking forward however to a remarkable turnaround in the SP this FY18.
- Forums
- ASX - By Stock
- BCT
- Ann: Annual Report
Ann: Annual Report, page-5
-
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BCT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.616M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BCT (ASX) Chart |
Day chart unavailable